Compounding Chemotherapy Market Report 2026

The compounding chemotherapy market size has grown strongly in recent years. It will grow from $6.11 billion in 2025 to $6.49 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to limited availability of compounding technologies, increasing cancer prevalence, reliance on hospital-based compounding, growing awareness of cytotoxic drug safety, adoption of manual preparation methods.

The compounding chemotherapy market size is expected to see strong growth in the next few years. It will grow to $8.2 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of automated and robotic compounding systems, expansion of homecare chemotherapy services, rising investment in sterile pharmacy infrastructure, increasing regulatory compliance for personalized medicine, growth in targeted therapies and immunomodulatory agents. Major trends in the forecast period include growing adoption of personalized chemotherapy formulations, integration of robotic compounding systems, expansion of homecare and specialty clinic compounding, rising focus on sterile and contamination-free environments, increased demand for supportive care drug compounding.

The rising prevalence of cancer cases is anticipated to drive the growth of the compounding chemotherapy market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The increasing incidence of cancer is largely attributed to unhealthy lifestyle factors such as poor nutrition, physical inactivity, smoking, excessive alcohol consumption, and prolonged exposure to environmental pollutants, all of which significantly elevate the risk of developing various forms of cancer. Compounding chemotherapy supports cancer treatment by enabling customized medication formulations tailored to the specific needs of individual patients, thereby improving therapeutic effectiveness and reducing adverse side effects. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government healthcare agency, there were 354,820 new cancer diagnoses reported in 2023, averaging 972 cases per day, which was 8,605 more than in 2022. Therefore, the increasing prevalence of cancer cases is contributing to the growth of the compounding chemotherapy market.

Major companies operating in the compounding chemotherapy market are concentrating on the development of advanced solutions, such as robotic chemotherapy automation systems, to improve accuracy, safety, and operational efficiency in the preparation of personalized cancer therapies. Robotic chemotherapy automation systems are sophisticated technologies designed to precisely and safely compound individualized chemotherapy doses by automating the preparation process, thereby minimizing the risk of human error and contamination. For instance, in February 2024, Simplivia Healthcare Ltd., an Israel-based healthcare technology company, introduced Smart Compounders Advanced Systems to automate and optimize the preparation of cytotoxic chemotherapy drugs. These systems are capable of compounding cytostatics and antibodies at a rate of 20 to 40 preparations per hour and include automatic gravimetric verification and comprehensive documentation to ensure high precision. They also significantly reduce pharmacy staff exposure to hazardous substances and are engineered to seamlessly integrate into existing laminar airflow cabinets or isolators without the need for structural modifications.

In June 2025, H.I.G. Capital LLC, a US-based investment firm, acquired ITH Group Limited for $70 million. Through this acquisition, H.I.G. Capital aims to support ITH Group’s organic expansion, increase production capacity, and strengthen its digital pharmacy capabilities. ITH Group Limited is a UK-based provider specializing in aseptic compounding services, including the preparation of chemotherapy medications.

Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Option Care Health Inc., ICU Medical Inc., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, McGuff Compounding Pharmacy Services Inc., Epicur Pharma LLC, PharMEDium Services LLC.

North America was the largest region in the compounding chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the compounding chemotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the compounding chemotherapy market by increasing the cost of imported robotic arms, sterile compounding equipment, and specialized drug containers. Hospital compounding and specialty clinic segments are particularly affected, with Asia-Pacific regions including China and India seeing significant price increases due to import duties. This has raised operational costs and slowed adoption in some areas, but tariffs also promote local manufacturing and innovation in compounding technologies, encouraging investment in domestic solutions.

The compounding chemotherapy market research report is one of a series of new reports that provides compounding chemotherapy market statistics, including compounding chemotherapy industry global market size, regional shares, competitors with a compounding chemotherapy market share, detailed compounding chemotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the compounding chemotherapy industry. This compounding chemotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Compounding chemotherapy involves the tailored preparation of chemotherapy medications by qualified pharmacists or technicians to meet the specific dosage, formulation, or combination needs of individual patients. This process includes the careful handling, mixing, and labeling of cytotoxic drugs within a controlled and sterile environment to ensure precision and patient safety.

The main drug types involved in compounding chemotherapy include cytotoxic drugs, hormonal agents, immunomodulatory agents, targeted therapies, and supportive care drugs. Cytotoxic drugs are agents that kill or damage cells and are widely used in cancer treatment to eliminate rapidly dividing cancer cells. These medications can be administered through various routes, including intravenous, oral, subcutaneous, intramuscular, and intrathecal. The compounding process may employ technologies with or without robotic arms. Distribution is carried out through hospital pharmacies, retail pharmacies, and online pharmacies, and services are provided across settings such as hospital compounding units, compounding pharmacies, specialty clinics, and home care environments.

The compounding chemotherapy market consists of revenues earned by entities by providing services such as labeling and packaging services, dose verification and clinical review, home infusion support services, cold chain logistics and delivery services, and clinical trials drug support. The market value includes the value of related goods sold by the service provider or included within the service offering. The compounding chemotherapy market also includes sales of chemotherapy drugs, compounding devices, infusion bags and syringes, personal protective equipment, and cleanroom and isolator systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.